PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 14, 2026Open Forum Infectious Diseases0 citationsOpen Access

P-167. The Utility of Microbial Cell Free DNA in the Rapid Diagnosis of Acute Chagas Disease

View Full Paper
AAAnissa AmilhamjaASAdam ShaikhKMKristin Mondy

Key Points

  • This research aims to evaluate microbial cell-free DNA testing as a diagnostic tool for acute Chagas disease.
  • Analyzed patients diagnosed with Chagas disease using the Karius Spectrum test
  • Collected data on clinical and demographic information across four institutions
  • Assessed turnaround times and patient management impact
  • Five patients tested positive for T. cruzi using the Karius Spectrum test; four cases were previously unrecognized
  • Symptoms included fever, with varying severity and conditions leading to empirical treatment
  • Test turnaround time ranged from 2 to 5 days; three patients showed improvement while two expired

Abstract

Abstract Background Chagas disease (CD), caused by Trypanosoma cruzi, is a vector-borne infection with potentially severe cardiac and neurological complications during acute infection or reactivation. Endemic to Latin America, sporadic cases also occur in the United States. Diagnosis of acute CD is by microscopy of whole blood or tissue and/or a polymerase chain reaction (PCR) test, however, sensitivity of microscopy may be lower in labs that do not routinely perform it. PCR is more sensitive and is available through commercial send-out labs, but due to the non-specific nature of acute CD, diagnosis is less likely to be considered outside of highly endemic areas. Microbial cell-free DNA (mcfDNA) testing, such as the Karius Spectrum® test, is a noninvasive diagnostic modality with broad pathogen detection. Karius may be particularly valuable when the diagnosis is not suspected or when infection is suspected but there are delays or barriers to traditional testing. Here we report five cases—one child and four adults—of CD diagnosed by microbial cell-free DNA testing.Figure 1.Echocardiogram of a 12-month-old male showing thrombus. A: Thrombus in the left ventricle apex measuring 6x7 mm and 6x6 mm, bilobed or two adjacent clots. Small to moderate pericardial effusion. B: Resolution of left ventricle thrombus.Figure 2.Brain MRI of an 88-year-old female with necrotizing encephalitis demonstrating bilateral frontoparietal enhancing white matter changes and surrounding vasogenic edema. Methods We collected clinical, laboratory and demographic information on patients diagnosed with CD using the Karius Spectrum® test, turnaround time, and impact on the management of the patients at four institutions: Driscoll Children’s Hospital, Dell Medical Center, Froedtert Hospital, and UCLA Medical Center.Figure 3.Chagoma on upper right arm of a 71-year-old female presenting as a raised, circular erythematous lesion (∼5 cm).Figure 4.41-year-old male with Romana’s sign on left eye. Results Five patients (4 adults, 1 child) tested positive for T. cruzi by the Karius Spectrum® test; diagnosis was not initially suspected in four. One case involved suspected Chagas reactivation. Patients (2 male, 3 female; ages 12 months–88 years) presented with fever and variable symptoms. Four were started on empiric therapy before results. Test turnaround was 2–5 days. Three improved after treatment; two expired. Case 1: 12-month-old male with cardiomyopathy (Figure 1). Case 2: 88-year-old female with necrotizing encephalitis (Figure 2). Case 3: 71-year-old female with Chagoma and cellulitis (Figure 3). Case 4: 41-year-old male with orbital cellulitis (Figure 4). Case 5: 50-year-old female with reactivation of known CD. Conclusion The detection of microbial cell free DNA in blood can rapidly confirm the diagnosis of Chagas disease and it is a particularly valuable test when the diagnosis is not clinically suspected. Disclosures All Authors: No reported disclosures

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Amilhamja et al. (2026) studied this question.

synapsesocial.com/papers/6966f2e313bf7a6f02c001b3https://doi.org/10.1093/ofid/ofaf695.391
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biomarkers for the diagnosis, treatment follow‐up, and prediction of cardiac complications in Chagas disease in chronic phase: Recent advances2023 · 3 citations
  2. 2A-302 Epidemiological Profile of Chagas Disease in Brazil: A study of Serological Test Data from 2023-20242025
  3. 3Severity of Chagasic Cardiomyopathy Is Associated With Response to a Novel Rapid Diagnostic Test for Trypanosoma cruzi TcII/V/VI2018 · 29 citations
  4. 4Detection of Trypanosoma Cruzi DNA in Blood by PCR is Associated with Chagas Cardiomyopathy and Disease Severity2015 · 64 citations
  5. 5Chagas disease2026 · 1 citations